The specialty’s leading advocate, the Advocacy Council, is committed to bringing you news and insights on billing, coding and policy reform that directly affect your practice. Advocacy Insider, a recurring column in College Insider, keeps you in the loop.
FDA Issues Memorandum of Understanding on compounded drugs
The Food and Drug Administration (FDA) recently issued a Memorandum of Understanding (MOU) related to the interstate distribution of compounded drugs. If a sta…
USP Appeals Upheld
On March 12, USP announced that the USP Appeals Panel had issued final decisions on the appeals to revisions to General Chapters <795>&nbs…
Update on USP Chapter <797>
When will the new standards be implemented?You may be wondering when the final deadline for implementation of the new United States Pharmacopeia (USP) Chapter …
Advocacy Council and the AMA – Part I
The United States Pharmacopeia (USP) is a scientific nonprofit organization, originally founded by physicians; it sets public standards for the identity, stren…
The latest update on USP 797 standards
The College’s Advocacy Council recently attended a call convened by the American Medical Association (AMA) with the physician community on compounding is…
Take the updated allergenic extract preparation quiz
There’s been considerable concern regarding the changes the revision of USP Chapter 797 has brought to practices. Don’t worry – the College a…
Do you have questions about the new USP Chapter 797standards?
Many of us have questions about the new USP standards. Here are two that members have asked us for guidance on:Q. Can the allergenic extract compounding area (…
Are you ready for new USP standards?
It’s important to be compliant with the upcoming new USP 797 standards. We know you have questions and concerns. We have it covered!To start, take a look…
A look behind…and ahead
2018 was a busy year for the College’s Advocacy Council as we worked hard to provide substantive advocacy services to College members. We’ve had so…
Billing for venom testing and immunotherapy
As we noted in last week’s Insider, there continues to be concerns about pricing and adequate availability of venoms for testing and treatment. We also u…
